News
3 No-Brainer Stocks to Buy in June
Sell in May and go away? The old adage hasn't proven to be great advice in 2023. The stock market has risen so far in June and could go even higher.
Three Motley Fool contributors think some stocks
2 Top Biotech Stocks to Buy in June
Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on
2 Top Biotech Stocks to Buy in June
Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on
2 Top Biotech Stocks to Buy in June
Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on
1 Stock Down 83% That Could Triple, According to Wall Street
Biotech company Novavax (NASDAQ: NVAX) has fallen from grace over the past year, with the vaccine maker's shares dropping by 84% over the trailing-12-month period. But Wall Street hasn't given up on
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is AbbVie or Amgen the Better Bargain Buy Right Now?
When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task
Is AbbVie or Amgen the Better Bargain Buy Right Now?
When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task
Is AbbVie or Amgen the Better Bargain Buy Right Now?
When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task
Can This Gene-Editing Stock Deliver 10X Returns?
Not many stocks are truly capable of generating a 1,000% return on investment within a reasonable time frame. Even so, a fair number of next-generation technology stocks have hit this lofty
This Red-Hot Growth Stock Has Soared 885% in Just 12 Months
Buying a soaring growth stock can be both exciting and risky territory for investors. In the biotech world, all it often takes is news of an approval from the Food and Drug Administration (FDA) or
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). The company is the global leader in cystic fibrosis (CF) treatments. And these products
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). The company is the global leader in cystic fibrosis (CF) treatments. And these products
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). The company is the global leader in cystic fibrosis (CF) treatments. And these products
2 Unstoppable Stocks to Buy Before the Bull Market
The market has been showing signs of life this year, but the S&P 500 remains down 10% since peaking in 2022. In a full-blown bull market, many businesses could see their valuations skyrocket
2 Unstoppable Stocks to Buy Before the Bull Market
The market has been showing signs of life this year, but the S&P 500 remains down 10% since peaking in 2022. In a full-blown bull market, many businesses could see their valuations skyrocket
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Drug Maker Merck Sues US Gov. Over Inflation Reduction Act
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.
The war on drug
Why NovoCure Stock Is Crashing Today
Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of 10:19 a.m. ET on Tuesday. The steep decline came after the company announced data for its Tumor Treating Fields (TTFields) therapy
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
One of the exciting parts of investing is identifying companies that will offer us the next big thing. This could be a game-changing drug or an exciting technology that may transform healthcare. And
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc